8 December, 2011
The bad drug lawsuit attorneys at AvandiaRecallNews.com no longer are accepting new Avandia cases. We continue to help families affected by Zoloft birth defects.
Our lawyers are accepting and aggressively litigating nationwide Zoloft Lawsuit claims to collect damages for Zoloft birth defects.
Call us now at 800-845-6913 or click this link for Zoloft Lawsuit Information.
Let us help you and your child recover the Zoloft birth defects compensation you deserve.
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia Lawsuit | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report | Avandia Settlements | Avandia Side Effects | Avandia Warning | Congestive Heart Failure18 November, 2010
Since its FDA approval in 1999, Avandia heart attack, stroke, heart failure and heart related death side effects have led to safety alerts, black box warnings, and bad drug lawsuit settlements.
A timeline of events alerting diabetes patients, the FDA and Avandia lawsuit attorneys of the heart attack and other cardiovascular risks associated with the diabetes drug. Continue reading Avandia Timeline: Diabetes Drug Side Effects, FDA Warnings
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia Senate Report | Avandia Side Effects30 September, 2010
Last week, an Avandia recall in Europe was announced as the FDA put tight new restrictions on Avandia use in the United States.
Avandia has been on the market in the U.S. to treat type 2 diabetes since 1999. How long have drug maker GlaxoSmithKline and the FDA been aware of Avandia side effects risks? According to a lead Senate investigator, the answer is shocking. Continue reading Avandia Recall News: GSK hid Rosiglitazone side effects risks
Category: Avandia FDA | Avandia Lawsuit | Avandia News | Avandia Senate Report | Avandia Settlements | Avandia Side Effects10 August, 2010
A new law has been been proposed to give the FDA authority to recall dangerous drugs.
Currently, the FDA can only require warnings, issue safety alerts and recommend that a dangerous drug be recalled. The Drug Safety and Accountability Act of 2010 would give the FDA power to recall drugs it determines to be unsafe. Continue reading New law would give FDA drug recall power
Category: Avandia FDA | Avandia Recall | Avandia Senate Report24 April, 2010
Avandia safety assessment at July meeting of joint FDA committees to lead to TIDE Trial decision.
When the FDA convenes a joint meeting of its Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management Advisory committees in July, the agency will assess the cardiovascular safety of Avandia and decide whether the controversial TIDE… Continue reading Assessment of Avandia Safety at July FDA meeting to lead to TIDE Trial decision
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report21 April, 2010
An Avandia safety study called the TIDE trial may be suspended by the FDA over Avandia heart attack risks.
Calls for an Avandia recall have been renewed over concerns that the diabetes drug increases heart risks. In February, a critical Senate report on Avandia was released following a two-year Senate Finance Committee investigation… Continue reading FDA may suspend Avandia safety study, could lead to Avandia recall
Category: Avandia Cardiovascular Risk | Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report11 March, 2010
Avandia heart side effects lawsuits could cost GlaxoSmithKline up to $6 billion, said UBS analysts in a note made public last week.
The UBS note follows a highly critical report on the drug by the U.S. Senate Finance Committee. Over 13,000 Avandia personal injury and wrongful death lawsuits currently are pending against the GSK… Continue reading Avandia side effects lawsuit settlements could top $6 billion in liability for GSK
Category: Avandia Lawsuit | Avandia News | Avandia Senate Report | Avandia Settlements | Avandia Side Effects | Avandia Warning6 March, 2010
Avandia drug company GlaxoSmithKline defends its popular diabetes drug in a 30-page “white paper” released February 24 rejecting a recent Senate Report stating that GSK downplayed the safety risks of their diabetes treatment Avandia. The prescription drug maker attacks the Senate Finance Committee’s January 2010 report on Avandia, claiming it is inaccurate, unbalanced and gives Continue reading Avandia maker GlaxoSmithKline releases "White Paper Response" to Senate Report on Avandia
Category: Avandia FDA | Avandia News | Avandia Recall | Avandia Safety | Avandia Senate Report